Drug Profile

Ondansetron controlled-release - Shilpa Medicare

Alternative Names: OERIS; Ondansetron extended-Release injection - Shilpa Medicare

Latest Information Update: 09 Jan 2026

Price :

$50 ^*

Note:

Adis is an information provider. We do not sell or distribute actual drugs.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

Originator Shilpa Medicare
Class 3-ring heterocyclic compounds; Anti-inflammatories; Antiemetics; Antipsychotics; Carbazoles; Cyclohexanones; Drug withdrawal therapies; Imidazoles; Indoles; Irritable bowel syndrome therapies; Obesity therapies; Small molecules; Smoking cessation therapies
Mechanism of Action Serotonin 3 receptor antagonists

Orphan Drug Status

Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

No
New Molecular Entity No

Highest Development Phases

Phase III Chemotherapy-induced nausea and vomiting

Most Recent Events

30 Nov 2025 Chemical structure information added.
28 Nov 2025 Shilpa Medicare completes a phase III SMLINJ011 trial in Chemotherapy-induced nausea and vomiting in India(controlled release)
11 Nov 2025 Phase-III clinical trials in Chemotherapy-induced nausea and vomiting in India (controlled release) prior to November 2025

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com